Company Directory / Biotechnology
Public · NASDAQ:IMCRFor profitBiotechnologyAbingdon, England, United Kingdom
Immunocore
Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.
- Founded
- 2008 18 years ago
- Staff
- 251-500 577 on LinkedIn
- Followers
- 39k on LinkedIn
- Funding
- $1.2B as listed, USD
Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr
Set against six million companies
Size
251-500 people: larger than 92% of companies with a size listed. 577 people list it on LinkedIn.
Age
18 years old.
Reach
Website ranked #1,349,159 in the world for traffic, about 19k visits a month. 39,055 followers on LinkedIn.
What it does
BiotechnologyHealth CareMedicalPharmaceuticalBiotechnologyCancerOncologyInfectious DiseasesAutoimmune DiseasesT Cell ReceptorImmunotherapyImmTAXImmTACImmTAVImmTAAI
Funding, as listed
$1.2B raised in total
- Rounds8
- LatestPost ipo debt, Jan 2024
- Latest amountUSD 350,000,000
- Investors13, 6 leading
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Every detail we hold
Everything the source datasets list about Immunocore, field by field. Contact details are held but never shown.
The company
- Name
- Immunocore
- Type
- For profit
- Status
- Public · NASDAQ:IMCR
- Founded
- 2008
- Founders
- Bent Jakobsen, Nick Cross
- Industry
- Biotechnology
- Categories
- Biotechnology, Health Care, Medical, Pharmaceutical
- Specialities
- Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, ImmTAAI
Where
- City
- Abingdon
- Region
- England
- Country
- United Kingdom
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 251-500
- People on LinkedIn
- 577
- LinkedIn followers
- 39,055
- Web traffic rank
- #1,349,159
- Monthly web visits
- 19,374
Funding, as listed
- Total
- $1,158,834,313 USD
- Rounds
- 8
- Latest round
- Post ipo debt
- Latest round date
- Jan 2024
- Latest amount
- 350,000,000 USD
- Investors
- 13
- Lead investors
- 6
- Stock listing
- NASDAQ:IMCR
- Listing status
- public
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Growth, as the source summarises it
Immunocore may be growing as indicated by their full year 2023 earnings report, which showed that revenues exceeded expectations. This financial performance suggests an upward trajectory in the company's sales or market demand for its products. Additionally, the first-quarter earnings report has prompted analysts to reassess the stock, implying that there may have been notable financial results or company developments that caught their attention. Furthermore, the company's financial statements have been the subject of analysis, indicating that there is a significant interest in Immunocore's financial health and performance.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Biotechnology in United Kingdom.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.